Despite the recent advances in cancer therapeutics, highly aggressive forms, such as glioblastoma (GBM), still have very low survival rates. The intracellular scaffold protein syntenin, comprising two postsynaptic density protein-95/discs-large/zona occludens-1 (PDZ) domains, has emerged a novel therapeutic target malignant phenotypes including GBM. Here, we report development of novel, potent,...